16 results on '"Licitra, L"'
Search Results
2. Zanzalintinib Plus Pembrolizumab Versus Pembrolizumab Alone In Patients with PD-L1 Positive Metastatic Head And Neck Squamous Cell Carcinoma (STELLAR-305): A Double-Blind, Randomized, Placebo-Controlled, Phase 2/3 Study
3. Health-Related Quality of Life (HRQoL) Data From KEYNOTE-412: Chemoradiotherapy (CRT) with or Without Pembrolizumab (pembro) in Patients (pts) with Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
4. Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study
5. Genomic Adjusted Radiation Dose (GARD) Predicts Overall Survival and Outperforms AJCC 8th Edition in Prognostication of HPV-Positive Oropharyngeal Squamous Cell Carcinoma
6. Phase 2 LEAP-009: Lenvatinib (Lenva) With or Without Pembrolizumab (Pembro) vs. Chemotherapy (Chemo) for Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That has Progressed on Platinum and Immunotherapy
7. Trilynx: A Phase 3 Trial of Xevinapant and Concurrent Chemoradiotherapy (CRT) for Locally Advanced Head and Neck Cancer
8. A Clinically Translatable, Extensively Validated Immune-based Classification of Human Papillomavirus-Associated Head and Neck Cancer With Implications for Treatment Deintensification and Immunotherapy
9. PCN72 An EARLY Cost-Effectiveness Analysis of Xevinapant in Combination with Chemo-Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck in United States.
10. Introducing Information on Saliva Microbiota into Toxicity Modeling: Preliminary Results from a Trial
11. Survey of the Adoption of the UICC/AJCC 8th Edition TNM for Head and Neck Cancer: The User’s Initial Experience
12. Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups
13. Association Between Toxicity Profiles During Radiation Therapy (RT) for Oropharyngeal Cancer and CBCT-Derived and Dosimetric Factors to Evaluate Global Toxicity During RT for Oropharyngeal Cancer
14. Prognostic Value of Metabolic Parameters by 18F-FDG PET/CT in Nasopharyngeal Cancer (NPC) in Non-Endemic Area
15. Tumor Biomarker Association With Clinical Outcomes in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Patients (Pts) Treated With Afatinib Versus Methotrexate (MTX): LUX-Head & Neck 1 (LHN1)
16. Patterns of Failure after Intensity Modulated Radiation Therapy (IMRT) and Chemotherapy for Patients with Nasopharyngeal Carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.